EBSEmergent BioSolutions Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Price is −20% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How EBS is trading
Emergent BioSolutions Inc. is −31% over the past year while the S&P 500 is +18%: 50 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −20%
vs 200-day average · a clear downtrend
- RSI (14)
- 51
RSI (14) · neutral
- Below its 52-week high
- 51%
Below its 52-week high
Details›
- Last close2026-10-08
- $6.81
- 1 monthS&P 500 +1.6%
- +20%
- 1 yearS&P 500 +18%
- −31%
- 5 yearsS&P 500 +86%
- −86%
- vs 50-day average$6.10
- +12%
- 52-week high
- $13.90
- 52-week low
- $4.45
- Annualised volatility
- 85%
| Year | Return |
|---|---|
| 2026 (year to date) | −45% |
| 2025 | +29% |
| 2024 | +298% |
| 2023 | −80% |
| 2022 | −73% |
| 2021 | −51% |
| 2020 | +66% |
| 2019 | −9.0% |
| 2018 | +28% |
| 2017 | +42% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +2.2% |
| Feb | 10 | 4 of 10 | +0.95% |
| Mar | 10 | 2 of 10 | −9.2% |
| Apr | 10 | 4 of 10 | −5.5% |
| May | 10 | 6 of 10 | +23% |
| Jun | 10 | 5 of 10 | +1.7% |
| Jul | 11 | 7 of 11 | +13% |
| Aug | 11 | 4 of 11 | −7.0% |
| Sep | 11 | 7 of 11 | −0.29% |
| Oct | 11 | 5 of 11 | −1.4% |
| Nov | 10 | 5 of 10 | −3.1% |
| Dec | 10 | 5 of 10 | +2.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore